Welcome to our dedicated page for Traws Pharma news (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.
Traws Pharma Inc (ONTX) is a clinical-stage biopharmaceutical company advancing novel cancer therapies through targeted small molecule drug development. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress and corporate developments.
Access official press releases, clinical trial milestones, and financial filings in one centralized location. Our curated collection includes updates on translational research breakthroughs, regulatory submissions, and strategic partnerships relevant to ONTX's oncology pipeline.
Key content categories include clinical program advancements, intellectual property developments, and financial performance reports. All materials are sourced directly from company communications and verified financial disclosures to ensure accuracy.
Bookmark this page for streamlined tracking of Traws Pharma's progress in developing precision therapies that aim to improve cancer treatment outcomes. Check regularly for updates on their proprietary drug discovery platform and pipeline candidates moving through clinical evaluation.
Onconova Therapeutics (NASDAQ: ONTX) announced significant findings from a preclinical study published in Molecular Cancer, showcasing rigosertib's ability to enhance immune checkpoint blockade (ICB) efficacy in melanoma models resistant to ICB alone. The study demonstrated that rigosertib reversed immunosuppressive tumor microenvironments, leading to better tumor growth inhibition and increased survival rates. This compelling evidence supports rigosertib's potential in clinical evaluations alongside immune checkpoint inhibitors, addressing an unmet need in cancer therapy.
Onconova Therapeutics, a clinical-stage biopharmaceutical company focused on cancer treatments, will participate in A.G.P.’s Virtual Summer Healthcare Symposium on June 17, 2021. Investors can engage in 1-on-1 virtual meetings with Onconova’s management. The company is advancing its proprietary multi-kinase inhibitor ON 123300 in Phase 1 studies in the U.S. and China, and is also studying rigosertib in targeting KRAS+ non-small cell lung cancer. For more, visit www.onconova.com.
Onconova Therapeutics (NASDAQ: ONTX) has been selected to present at the 2021 BIO Digital event scheduled for June 10-11 and June 14-18. Dr. Steven Fruchtman, the company's President & CEO, will outline Onconova's corporate development objectives and milestones for its lead candidate ON 123300 during the virtual presentation. Registrants can access the presentation starting at 9:00 am ET on June 10. Additionally, Onconova is conducting Phase 1 studies for ON 123300 in the U.S. and China and continues research on rigosertib for various cancer treatments.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) has appointed Dr. Mark Gelder as Chief Medical Officer, effective June 14, 2021. Dr. Gelder brings over 35 years of experience in clinical development and oncology, having previously served as CMO at Elevar Therapeutics and holding senior roles in large pharmaceutical companies like Pfizer and Bayer. His expertise in developing kinase inhibitors is seen as valuable for advancing Onconova’s product pipeline, notably the multi-kinase inhibitor ON 123300, currently in Phase 1 trials. The leadership change is expected to enhance Onconova's strategic direction.
Onconova Therapeutics has initiated a Phase 1 clinical trial for ON 123300, a novel multi-kinase inhibitor targeting advanced cancers, particularly HR+ HER 2- metastatic breast cancer patients resistant to current CDK 4/6 inhibitors. The trial includes three U.S. sites and aims to determine the safety, tolerability, and pharmacokinetics of ON 123300. Initial dosing has commenced at 40 mg daily for 28-day cycles, with potential expansion to additional cancer indications. The collaboration with HanX Biopharmaceuticals on a parallel trial in China is also highlighted.
Onconova Therapeutics, a clinical-stage biopharmaceutical company, announced a one-for-fifteen reverse stock split effective May 20, 2021. This decision, approved by stockholders at their annual meeting, reduces the number of common shares from approximately 236.714 million to about 15.781 million. The company's authorized shares will also decrease from 255 million to 130 million. Following the split, tradable warrants will be adjusted accordingly. Onconova’s common stock will continue to trade under the symbol ONTX on the Nasdaq Capital Market.
Onconova Therapeutics (NASDAQ: ONTX) reported financial results for Q1 2021, highlighting key advancements in clinical trials. The ongoing Phase 1 study of ON 123300 in solid tumors shows no dose-limiting toxicities, with the third cohort set to enroll. The company has $48 million in cash, sufficient for over 18 months of operations. Q1 net loss was $4.7 million, an improvement from $5.1 million in Q1 2020. Onconova is focused on advancing ON 123300 and rigosertib programs, with promising developments in multiple studies aimed at cancer treatment.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) plans to release its Q1 2021 financial results on May 17, 2021, followed by a conference call at 4:30 p.m. ET. The company is focused on developing novel cancer therapies, including multi-kinase inhibitor ON 123300, which will enter a Phase 1 trial in the U.S. during Q2 2021. Additionally, Onconova is studying oral rigosertib in KRAS+ lung adenocarcinoma. Stakeholders can access the call via phone or through the company's website, where a replay will be available for 90 days.
Onconova Therapeutics (NASDAQ: ONTX) announced the first patient dosing in a Phase 2 study evaluating rigosertib for squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa (RDEB). Conducted at EB House Austria, the study will enroll 12 patients, testing both oral and intravenous forms of rigosertib. The primary endpoints include assessing anti-tumor activity and safety. The trial aims to address the significant unmet need in RDEB SCC, where skin carcinoma is a leading cause of death. Duration is expected to be approximately two-and-a-half years.
Onconova Therapeutics (NASDAQ: ONTX) announced that its partner, HanX Biopharmaceuticals, has enrolled three patients in the 80 mg cohort of the Phase 1 trial of ON 123300 for HR+ HER2- metastatic breast cancer in China. To date, six patients have been enrolled across two cohorts. The study aims to identify a recommended Phase 2 dose, with a third cohort at 120 mg expected soon. Onconova plans to begin its own U.S. trial in Q2 2021. ON 123300 is a multi-kinase inhibitor that targets advanced cancers resistant to current treatments.
